CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
| Website: | www.cel-sci.com |
| Email: | gdewindt@cel-sci.com |
| Main Phone: | +1 703 506-9460 |
| Address: | 8229 Boone Boulevard |
| Address 2: | Suite 802 |
| State: | VA |
| City / Town: | Vienna |
| Country: | US |
| Postal Code: | 22182 |
| Exchange: | AMX |
| CEO: | Geert R. Kersten |
| Employees: | 44 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)
Cel-Sci Corporation (CVM) saw its stock plunge after pricing a public offering of over 7 million shares of stock. Pricing the units at $1.40 apiece for gross proceeds of $10 million. Each unit
Today was a rough day for Internet retailers and service providers. First, Netflix (NASDAQ: NFLX) made headlines with an 8.8 percent drop for the day and now online mega-retailer Amazon
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
| Website: | www.cel-sci.com |
| Email: | gdewindt@cel-sci.com |
| Main Phone: | +1 703 506-9460 |
| Address: | 8229 Boone Boulevard |
| Address 2: | Suite 802 |
| State: | VA |
| City / Town: | Vienna |
| Country: | US |
| Postal Code: | 22182 |
| Exchange: | AMX |
| CEO: | Geert R. Kersten |
| Employees: | 44 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)
Cel-Sci Corporation (CVM) saw its stock plunge after pricing a public offering of over 7 million shares of stock. Pricing the units at $1.40 apiece for gross proceeds of $10 million. Each unit
Today was a rough day for Internet retailers and service providers. First, Netflix (NASDAQ: NFLX) made headlines with an 8.8 percent drop for the day and now online mega-retailer Amazon
| Last Price 12.72 | Change $ 0.25 | Change % 2.00 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 12.31 | High 12.93 | Low 12.31 | Prev Close 12.47 |
| Last Trade | Volume 251,251 | 52 Wk Hi 18.00 | 52 Wk Low 6.00 |
| Market Cap 491.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 38,624,084.00 | EPS (TTM) 6,183,850.00 | PE Ratio N/A | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 13 | 33 |
| Number of Buys | 13 | 25 |
| Number of Sells | 0 | 8 |
| Net Activity | 307327 | 286692 |
| Last 10 Buys | Shares |
|---|---|
| Peter R. Young | 1,000 |
| Peter R. Young | 1,000 |
| Peter R. Young | 1,000 |
| Peter R. Young | 1,000 |
| Geert R. Kersten | 1,000 |
| Geert R. Kersten | 1,000 |
| Geert R. Kersten | 1,000 |
| Peter R. Young | 1,000 |
| Peter R. Young | 1,000 |
| Geert R. Kersten | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Eyal Talor | 1,000 |
| Eyal Talor | 1,000 |
| Eyal Talor | 1,000 |
| Eyal Talor | 1,000 |
| Eyal Talor | 1,000 |
| John Cipriano | 1,000 |
| Eyal Talor | 1,000 |
| Eyal Talor | 1,000 |
| De Maximilian Clara | 1,000 |
| C. Richard Kinsolving | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 3 | 3 | 3 | 3 |
| Mean Target Price Estimate | 3 | 3 | 3 | 3 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 12/16/15 | 12/16/15 | 12/16/15 | 12/16/15 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| S-1 | General form for registration of securities under the Securities Act of 1933 | 21 | 2018-05-24 |
| 8-K | Report of unscheduled material events or corporate changes. | 22 | 2018-05-21 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 32 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-03 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 3 | 3 | 3 | 3 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait